The global aldosteronism treatment demand is anticipated to increase at a robust CAGR of around 8% between 2022 and 2032. Growth in the market is driven by rising prevalence of primary aldosteronism across the world.
| Report Attribute | Details |
| Aldosteronism Treatment Market Projected Growth Rate (2022-2032) | ~8% CAGR |
Aldosteronism is a hormonal disorder in which the adrenal glands release excessive amounts of aldosterone into the blood. This disturbs the balance of sodium and potassium in the body, lowers renin levels, and therefore leads to high blood pressure. In order to treat this medical condition, people opt for various treatments such as surgeries and drugs.
There are two types of aldosteronism i.e., primary aldosteronism and secondary aldosteronism. Primary aldosteronism is a condition in which there is defect (such as tumor or enlargement) in the adrenal glands themselves while in secondary aldosteronism the problem lies in some other body parts or genes.
Presence of aldosteronism can cause symptoms such as high blood pressure, muscular aches and weakness, back pain, vertigo and excessive urination. If the condition, however, remains untreated, it can lead to severe complications including heart stroke, kidney failure, myocardial infarction and thus can be fatal. Therefore, detecting and treating aldosteronism becomes necessary.
Various treatments are available for aldosteronism, depending on the underlying cause of the condition. People with single benign tumor usually opt for adrenalectomy while as those with hyperplasia of both glands consume drugs that block the effect of aldosterone. Rising prevalence of aldosteronism coupled with growing inclination of people to treat this condition is the primary force behind the robust expansion of aldosterone treatment market.
Subsequently, introduction of novel therapeutic treatments for aldosteronism will further accelerate the growth of aldosterone treatment market during the forecast period. Leading market players are increasingly investing in research and development activities for introducing innovative drugs with minimum side effects.
Based on treatment type, non-surgical aldosteronism treatment category is anticipated to dominate the global aldosteronism treatment market during the forecast period. This is attributable to the better patient outcomes and availability of low-cost drugs.
Rising incidence of primary aldosteronism, growing geriatric populations, availability of various treatment options and rising health awareness among people are some of the major factors driving the global aldosteronism treatment market.
Over the last few years, demand for aldosteronism treatment has witnessed a significant rise due to an increase in aldosteronism cases and the trend is likely to continue in the future. People are increasingly opting for aldosteronism treatments like surgeries and drugs to restore the hormonal imbalance and ease symptoms.
Similarly, increase in diagnostic screening of aldosteronism due to easy availability and low cost of diagnostic tests is anticipated to boost the growth of aldosteronism treatment market during the forecast period.
In addition to this, growing popularity of minimally invasive procedures like laparoscopy for the effective treatment of aldosteronism will further expand the size of aldosteronism treatment market in the future. These minimally invasive surgeries have become standard treatment especially for people with single benign tumor (adenoma).
Despite its optimistic stance, the global aldosteronism treatment market is facing various challenges that are slowing down its growth to some extent. Some of these factors are the higher risks associated with surgical aldosteronism treatment and various side effects of consuming aldosteronism treatment drugs. It has been found that prolonged use of therapeutic drugs for aldosteronism can lead to side effects such as impotence and decreased sexual desire. As a result, many people refrain from using these drugs for longer period of time.
With rising prevalence of aldosteronism, higher expenditure on healthcare and presence of leading drug manufacturers, North America will continue its dominance in the global aldosteronism treatment market during the forecast period.
North America is home to some of the leading pharmaceutical companies and medical research institutions in the world. These companies are continuously striving to introduce novel treatments for diseases like cancer, hypertension and aldosteronism. Countries like the United States spend billions of dollars on medical researches annually.
Similarly, there has been a rapid increase in the diagnostic screening across the North American region during the last few years. This is acting as a catalyst for triggering the growth of aldosteronism market and the trend is likely to continue in the foreseeable future.
According to Future Market Insights, the Asia Pacific Aldosteronism Treatment Market is poised to grow at a faster CAGR over the forecast period, owing to the rising healthcare awareness, adoption of various aldosteronism treatments, increasing government support and presence of both regional and international market players.
Demand for aldosteronism treatments is particularly high across countries like China and India due to increasing hypertension patient pool and availability of various therapeutics at lower prices. Various studies have confirmed that primary aldosteronism is a relatively common cause of resistant hypertension. As a result, patients in these regions consume large amounts of aldosteronism drugs. Rise in hypertension cases will continue to boost the sales of therapeutics like calcium-channel blockers and potassium sparring diuretics in the future.
Some of the key participants present in the global aldosteronism treatment market include Pfizer Inc., Novartis AG, Allergan Plc., GE Healthcare, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd.
The global aldosteronism market is highly fragmented, with a large number of manufacturers holding significant share in various regions. These key players have adopted growth strategies such as new product launches, partnerships, collaborations, and establishment of new bases in attractive markets of Asia and Africa to expand their global footprint.
| Report Attribute | Details |
| Growth Rate | CAGR of 8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Treatment Type
By End User:
By Region:
FMI projects the global aldosteronism treatment market to expand at around 8% value CAGR by 2032.
Asia Pacific is expected to be the most opportunistic aldosteronism treatment market, expanding at robust CAGR over the forecast period.
Pfizer Inc., Novartis AG, Allergan Plc., GE Healthcare, Accord Healthcare, Teva Pharmaceutical Industries Ltd. are some prominent aldosteronism treatment market players.
Explore Similar Insights
Aldosteronism Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
